# Nevro Corp

其HFX iQ系统将AI驱动的个性化技术（HFX AdaptivAI）与10 kHz疗法相结合，已于2024年11月在欧洲获得CE认证，并基于SENZA-NSRBP随机对照试验获得FDA针对非手术性背痛的专项适应症批准。

Source: https://cn.bioecon.ru/companies/nevro-corp/
Updated: 2026-07-20

- 国家: United States
- 代码: NVRO

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 认证 | HFX iQ脊髓刺激系统在欧洲获CE标志认证 (2024-11-12) | https://intl.nevro.com/English/us/investors/investor-news/investor-news-details/2024/Nevros-HFX-iQ-Spinal-Cord-Stimulation-with-AI-Technology-Receives-CE-Mark-Certification-in-Europe-Increasing-Product-Expansion-Globally/default.aspx, https://www.massdevice.com/nevro-ce-mark-spinal-cord-stim-q3-2024/, https://www.prnewswire.com/news-releases/nevros-hfx-iq-spinal-cord-stimulation-with-ai-technology-receives-ce-mark-certification-in-europe-increasing-product-expansion-globally-302301647.html |
| 监管批准 | HFX iQ 系统在美国获得 FDA 批准 (2022-01-01) | https://intl.nevro.com/English/us/investors/investor-news/investor-news-details/2024/Nevros-HFX-iQ-Spinal-Cord-Stimulation-with-AI-Technology-Receives-CE-Mark-Certification-in-Europe-Increasing-Product-Expansion-Globally/default.aspx, https://www.prnewswire.com/news-releases/nevro-announces-the-launch-of-hfx-adaptivai-the-only-ai-driven-technology-in-spinal-cord-stimulation-302256481.html, https://www.prnewswire.com/news-releases/nevros-hfx-iq-spinal-cord-stimulation-with-ai-technology-receives-ce-mark-certification-in-europe-increasing-product-expansion-globally-302301647.html, https://www.sec.gov/Archives/edgar/data/1444380/000095017024127066/nvro-ex99_1.htm |
| 监管批准 | HFX AdaptivAI 在美国获得 FDA 批准 (2024-09-24) | https://trial.medpath.com/news/nevro-wins-fda-nod-for-ai-driven-spinal-cord-stimulation-tech-massdevice, https://www.prnewswire.com/news-releases/nevro-announces-the-launch-of-hfx-adaptivai-the-only-ai-driven-technology-in-spinal-cord-stimulation-302256481.html, https://www.prnewswire.com/news-releases/nevros-hfx-iq-spinal-cord-stimulation-with-ai-technology-receives-ce-mark-certification-in-europe-increasing-product-expansion-globally-302301647.html, https://www.sec.gov/Archives/edgar/data/1444380/000095017024127066/nvro-ex99_1.htm |
| 营收 | 2024全年全球收入为$4.085亿 (2024-12-31) | https://last10k.com/sec-filings/nvro/0001444380-25-000021.htm |
| 生产基地 | 生产设施位于哥斯达黎加 | https://www.prnewswire.com/news-releases/nevro-initiates-plan-for-manufacturing-operations-in-costa-rica-to-support-future-growth-301129871.html, https://www.sec.gov/Archives/edgar/data/1444380/000095017024019464/nvro-20231231.htm |

独立来源: intl.nevro.com, last10k.com, massdevice.com, prnewswire.com, sec.gov, trial.medpath.com

## 技术

- [生物电子医学与神经调控](https://cn.bioecon.ru/technology/bioelectronic-medicine-neuromodulation/)